FDA Class II Recall: Glenmark's Ranolazine Tablets Impacted by CGMP Deviations, Raising Supply Chain Concerns
Glenmark Pharmaceuticals Inc., USA has initiated a Class II recall (D-0335-2025) for Ranolazine Extended-Release Tablets 1000mg nationwide due to Current Good Manufacturing Practice (CGMP) deviations. This action, impacting lot 17240040, signals critical quality control deficiencies at the manufacturing site in Pithampur, India. Procurement and regulatory teams must assess supply chain risks and evaluate alternative Ranolazine sources to ensure continuity and compliance.
FDA Class II Recall: Glenmark's Ranolazine Impacted by CGMP Deviations
Glenmark Pharmaceuticals Inc., USA initiated a Class II recall, identified as D-0335-2025, on March 13, 2025, for its Ranolazine Extended-Release Tablets 1000mg. This significant regulatory action, which received its classification on April 8, 2025, stems directly from identified Current Good Manufacturing Practice (CGMP) deviations at the manufacturing facility, Glenmark Pharmaceuticals Limited in Pithampur, India. For procurement directors and supply chain VPs, this immediately signals a critical disruption risk for a key anti-anginal medication distributed nationwide across the U.S. The Class II classification indicates that while exposure to the violative product may cause temporary or medically reversible adverse health consequences, the probability of serious adverse outcomes is considered remote. However, the underlying CGMP issues raise significant concerns regarding product quality, consistency, and regulatory adherence, demanding immediate attention from regulatory affairs heads to assess compliance and risk exposure. The specific product affected is Ranolazine Extended-Release Tablets 1000mg, packaged in 60-count bottles, identified by NDC# 68462-320-60. The recall specifically targets Lot # 17240040, with an expiration date of December 2025. This precise identification is crucial for targeted inventory management and quarantine actions across the distribution network. Business development executives must recognize that such deviations can erode market confidence and potentially impact future product launches or partnerships involving Glenmark. The recall's ongoing status, as reported on April 16, 2025, means that the full scope of remediation and its impact on long-term supply stability for Ranolazine, a drug also identified by application number ANDA211082, remains uncertain, necessitating proactive risk mitigation strategies to safeguard business continuity.
Manufacturing Origin and Product Profile: Ranolazine Supply Chain Vulnerability
The Ranolazine Extended-Release Tablets subject to this Class II recall are manufactured by Glenmark Pharmaceuticals Limited in Pithampur, Madhya Pradesh, India, for Glenmark Pharmaceuticals Inc., USA, located in Mahwah, NJ. This international manufacturing arrangement highlights the inherent complexities of global pharmaceutical supply chains, where the quality standards and regulatory compliance of a foreign manufacturing site directly impact product availability and market access in the United States. For supply chain VPs, this situation underscores the imperative of establishing and maintaining robust oversight mechanisms that extend to all contract manufacturing organizations (CMOs) and international facilities, ensuring adherence to U.S. FDA CGMP standards. The product, Ranolazine, is a critical human prescription drug primarily used as an anti-anginal medication. Its broad pharmacological profile includes roles as a Cytochrome P450 3A Inhibitor, P-Glycoprotein Inhibitor, Cytochrome P450 2D6 Inhibitor, and Organic Cation Transporter 2 Inhibitor. The consistent availability of Ranolazine is vital for patient care, making any supply disruption due to CGMP deviations a significant concern for healthcare providers and patients alike. Procurement directors must immediately assess their inventory of Glenmark-sourced Ranolazine, specifically lot 17240040, and initiate quarantine procedures. The reliance on a single manufacturing site in India for a product distributed U.S. nationwide exposes the supply chain to single-point-of-failure risks, which regulatory affairs heads should address by reviewing their due diligence processes for foreign manufacturing sites, ensuring quality agreements and audit programs are sufficiently rigorous.
Commercial Impact: U.S. Nationwide Distribution and Market Exposure
The U.S. nationwide distribution pattern of Glenmark's Ranolazine Extended-Release Tablets means that this Class II recall has broad commercial implications for pharmacies, hospitals, and distributors across the United States. Procurement directors must promptly identify all affected inventory, specifically lot # 17240040, and coordinate returns or destruction as per FDA guidelines. Failure to do so could lead to significant financial losses from unusable stock, potential legal liabilities, and compromised patient safety. The recall, initiated on March 13, 2025, and classified on April 8, 2025, with an ongoing status as of April 16, 2025, requires continuous monitoring by all stakeholders involved in the pharmaceutical supply chain. For business development executives, this event may necessitate a re-evaluation of existing supply agreements and vendor relationships with Glenmark. The reputational damage associated with CGMP deviations and product recalls can be substantial, potentially affecting future market share for Glenmark and its partners in the competitive generic pharmaceutical landscape. Regulatory affairs heads must ensure that their organizations are fully compliant with all recall procedures, including accurate and timely communication with healthcare providers and patients to mitigate any adverse impacts. The disruption to the supply of Ranolazine, a human prescription drug available under NDCs 68462-319-60, 68462-319-05, 68462-320-60, and 68462-320-05, underscores the critical need for robust quality management systems throughout the entire supply chain, from the manufacturing origin in India to the point of distribution in the U.S.
Mitigating Supply Risk: Identifying Alternative Ranolazine Sources
Given the ongoing Class II recall of Glenmark's Ranolazine Extended-Release Tablets due to CGMP deviations, procurement directors must prioritize identifying and qualifying alternative suppliers to mitigate potential supply chain disruptions. While our current intelligence graph does not specify alternative manufacturers for Ranolazine, the market for generic pharmaceuticals typically features multiple approved Abbreviated New Drug Application (ANDA) holders. Companies should initiate a comprehensive market scan to identify other FDA-approved manufacturers of Ranolazine, focusing on those with strong compliance records and diverse geographic manufacturing footprints to avoid similar single-point-of-failure risks associated with a single facility in India. The qualification process for new pharmaceutical suppliers can be lengthy and resource-intensive, involving rigorous audits of manufacturing facilities, quality systems, and regulatory documentation. Regulatory affairs heads should prepare for the necessary due diligence, including reviewing Drug Master Files (DMFs) and potentially conducting site inspections to ensure compliance with U.S. FDA standards. Business development executives should consider this situation an opportunity to diversify their portfolio and strengthen overall supply chain resilience for critical molecules. Proactive engagement with potential alternative suppliers, understanding their capacity, lead times, and regulatory standing, is crucial to prevent stock-outs and maintain continuity of supply for this essential anti-anginal medication.
Regulatory Compliance Landscape: Broader Industry Context
While our current intelligence does not detail prior regulatory actions specifically against Glenmark Pharmaceuticals Inc., USA, or its Indian manufacturing facility, this Class II recall for CGMP deviations serves as a critical indicator of potential systemic quality control issues. Regulatory affairs heads should view this event as a prompt to intensify their internal audit programs and supplier qualification processes, particularly for products sourced from international facilities. The FDA's consistent enforcement of CGMP standards means that any identified deviation can lead to significant market actions, impacting product availability, company reputation, and ultimately, patient access to essential medicines. This event also aligns with broader industry trends in regulatory scrutiny, highlighting a heightened focus on manufacturing quality. For instance, recent parallel events in the life sciences sector include Essential Wellness Pharma's Class II recall of Progesterone Injection in June 2026 due to sterility assurance failures, and an FDA hearing in June 2026 regarding Amgen's Tavneos, which put its market future at risk amid an independent data review. These incidents collectively underscore a stringent regulatory environment where agencies like the FDA are actively enforcing compliance across various therapeutic areas. Procurement directors and supply chain VPs must recognize that robust quality systems are not merely a compliance burden but a fundamental component of business continuity and market access in the global pharmaceutical landscape.
Remediation and Future Outlook: Navigating Post-Recall Scrutiny
The "Ongoing" status of the Class II recall for Glenmark's Ranolazine Extended-Release Tablets signifies that the company is currently engaged in the recall process, including notifying customers and managing product returns. However, the underlying CGMP deviations demand a comprehensive and effective remediation effort from Glenmark Pharmaceuticals Limited in India. Regulatory affairs heads anticipate that the FDA will require a thorough root cause analysis, followed by the implementation of robust corrective and preventive actions (CAPA) to address the fundamental quality system deficiencies that led to the recall of lot # 17240040. This process is critical for restoring confidence in the manufacturing site's compliance. For procurement directors and supply chain VPs, the future availability and reliability of Glenmark's Ranolazine supply remain subject to the successful resolution of these CGMP issues and subsequent FDA verification. This could involve further inspections of the Pithampur facility to confirm the effectiveness of implemented CAPAs. Failure to adequately address the deviations could escalate into more severe regulatory actions, such as a Warning Letter, an Import Alert preventing future shipments to the U.S., or even product seizure. Business development executives should monitor Glenmark's progress closely, as sustained non-compliance could necessitate a complete re-evaluation of their partnership and sourcing strategies for Ranolazine and other products from this manufacturer, impacting long-term market presence.